Dr. Burris will serve as president of ASCO for the 2019-2020 term. He serves as president and chief medical officer of Sarah Cannon, as well as the executive director of drug development for the Research Institute. He is also an associate of Tennessee Oncology, PLLC, where he practices medical oncology. Dr. Burris' clinical research career has focused on the development of new cancer agents with an emphasis on first-in-human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies. In 1997, he established the first community-based early-phase drug development program in Nashville, which grew into the Sarah Cannon Research Institute.
Since joining ASCO in 1991, Dr. Burris has been elected and served as a member of the ASCO Board of Directors (2006-2009) as well as chair of the Nominating Committee (2012-2013).